Elanco Animal Health (NYSE:ELAN) Director Buys 5,000 Shares

Key Points

• Director Michael Harrington bought 5,000 Elanco shares at an average price of $21.82, investing $109,100 and increasing his direct ownership by 3.95% to 131,451 shares.
• Elanco’s latest quarter exceeded expectations, with adjusted earnings of $0.34 per share versus the $0.27 consensus and revenue of $1.37 billion, up 10.2% year over year.
• The stock traded at $22.52, while analysts maintained an overall “Moderate Buy” rating with a consensus price target of $29.09; institutional investors own 97.48% of shares.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) Director Michael Harrington bought 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average price of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Elanco Animal Health Price Performance

NYSE:ELAN traded up $0.39 on Thursday, reaching $22.52. The stock had a trading volume of 5,574,051 shares, compared to its average volume of 5,740,837. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $11.25 billion, a P/E ratio of -54.93, a price-to-earnings-growth ratio of 1.36 and a beta of 1.67. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98. The stock has a fifty day moving average price of $24.60 and a 200-day moving average price of $24.04.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company's revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ELAN. NewEdge Advisors LLC boosted its position in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after buying an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Elanco Animal Health during the second quarter worth $38,000. Root Financial Partners LLC raised its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock worth $40,000 after acquiring an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health during the fourth quarter worth $41,000. Finally, Torren Management LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter valued at $46,000. Institutional investors own 97.48% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Citigroup raised their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, July 31st. Finally, Wall Street Zen downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health presently has an average rating of "Moderate Buy" and a consensus price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source